Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21
Abstract
Campylobacter jejuni is a leading cause of diarrheal disease worldwide, and currently no preventative interventions are available. C. jejuni is an invasive mucosal pathogen that has a variety of polysaccharide structures on its surface, including a capsule. In phase 1 studies, a C. jejuni capsule conjugate vaccine was safe but poorly immunogenic when delivered alone or with aluminum hydroxide. Here, we report enhanced immunogenicity of the conjugate vaccine delivered with liposome adjuvants containing monophosphoryl lipid A without or with QS-21, known as ALF and ALFQ, respectively, in preclinical studies. Both liposome adjuvants significantly enhanced immunity in mice and nonhuman primates and improved protective efficacy of the vaccine compared to alum in a nonhuman primate C. jejuni diarrhea model, providing promising evidence that these potent adjuvant formulations may enhance immunogenicity in upcoming human studies with this C. jejuni conjugate and other malaria and HIV vaccine platforms.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 26, 2019
- Source ID
- 10.1128/msphere.00101-19
Entities
People
- Amritha Ramakrishnan
- Andrea J. Mccoy
- Carl R. Alving
- Christina L. Gariepy
- Frederic Poly
- Gary R Matyas
- Gladys Nunez
- Heather Eggleston
- Jesus Rojas
- Monica Nieto
- Nereyda Espinoza
- Nina M. Schumack
- Patricia Guerry
- Renée M. Laird
- Rosa Castillo
- Zoltan Beck
Organizations
- Henry M. Jackson Foundation
- Naval Medical Research Center
- U.S. Military HIV Research Program
- United States Navy